FDA authorizes platform that predicts COVID-19 complications
The FDA issued an emergency use authorization for CLEWICU, an artificial intelligence-based platform that identifies several COVID-19 complications hours before they occur, the manufacturer said in a press release.
“CLEWICU is a subscription software service deployed on the cloud that provides each customer a unique setup that varies based on many factors like size, term and integration needs,” Mitch Steiner, chief commercial officer of CLEW, told Healio Primary Care.
Gal Salomon, co-founder and CEO of CLEW, added that the company’s artificial intelligence-based algorithms were trained on 100,000 patients.
“CLEWICU provides predictive screening information to assist with the early identification of patients who are likely to be diagnosed with the common COVID-19 complications of respiratory failure or hemodynamic instability,” he said in an interview. “Additionally, a remotely located clinician can use CLEWICU to safely support ICUs and provide support to address overloading and understaffing.”
According to the release, the product’s “streamlined at-a-glance web application” also allows almost real-time access to patient information and offers tools for worklist and unit and multi-unit views. Those tools allow physicians to simultaneously view up to three “unique” sets of medical information, Steiner explained.
“A [physician] can view information at the patient, multiple patients, multiple units and/or multiple hospital level,” he said. “There is also a high priority worklist view, which provides the physician all the data necessary to make decisions on the patients” that are part of the CLEWICU process, Steiner added.
Several hospitals in the United States are already using CLEWICU, according to the release.